Arrowhead Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $75,253 | $73,737 | $264,033 | $256,472 |
Gross Profit | 75,253 | 73,737 | 264,033 | 256,472 |
EBITDA | -154,343 | -107,351 | 57,166 | 64,201 |
EBIT | -113,719 | 50,776 | 57,815 | |
Net Income | -194,280 | -132,732 | 30,811 | -23,750 |
Net Change In Cash | 75,253 | 73,737 | 264,033 | 256,472 |
Free Cash Flow | -181,323 | 81,877 | 11,333 | 13,002 |
Cash | 54,759 | 188,517 | 201,643 | 226,548 |
Basic Shares | 143,378 | 142,417 | 140,706 | 135,702 |
Annual Financials
| Values in thousands | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
Revenue | $829,448 | $3,551 | $240,735 | $243,231 |
Gross Profit | 829,448 | -15,044 | 228,242 | 243,231 |
EBITDA | 164,822 | -561,513 | -175,672 | -168,086 |
EBIT | 140,894 | -580,108 | -188,165 | -178,507 |
Net Income | -1,631 | -599,493 | -205,275 | -176,494 |
Net Change In Cash | 829,448 | 3,551 | 240,735 | 243,231 |
Cost of Revenue | -76,362 | |||
Free Cash Flow | 156,886 | -604,320 | -330,627 | -188,908 |
Cash | 226,548 | 102,685 | 110,891 | 108,005 |
Basic Shares | 133,758 | 119,784 | 106,750 | 105,426 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.36 |
2026-03-31 | -$0.93 |
2025-12-31 | $0.22 |
2025-09-30 | -$0.11 |